Better Buy: Celgene Corporation vs. Merck & Co.
Better Buy: Celgene Corporation vs. Merck & Co. Keith Speights, The Motley FoolMotley FoolNovember 17, 2018, 10:02 PM GMT. Two drug stocks diverged in a yellow wood. And sorry I could not buy both and be one investor, long I stood. My apologies to Robert Frost for butchering his famous poem "The Road Not Taken." But Celgene Corporation(NASDAQ: CELG) and Merck & Co.(NYSE: MRK) certainly are two drug stocks headed in different directions. Celgene faces generic competition for its best-selling drug beginning in 2022 at the latest. But the biotech expects to launch five new drugs over the next couple of years that arguably could replace all of the revenue generated by Revlimid.